Skip to main content
    C

    Cartesian Therapeutics Inc. (RNAC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $6.08
    -0.27 (-4.25%)

    Market Cap: $193.69M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    57%(23/40)
    Avg Surprise
    +17.38%
    Streak
    2 Q

    Upcoming Estimates

    Reports Mar 8, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.95
    Range-$1.18 - -$0.41
    9 analysts
    Revenue Consensus
    $348.50K
    RangeN/A
    9 analysts
    Reports Apr 28, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.86
    Range-$1.09 - -$0.42
    6 analysts
    EPS Revisions
    2
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$1.05+18.2%
    60d ago-$1.05+18.2%
    30d ago-$1.05+18.2%
    7d ago-$1.05+18.2%
    Current-$0.86
    Revenue Consensus
    $41.67K
    RangeN/A
    6 analysts

    Key Metrics

    Valuation
    P/E RatioN/AEV/EBITDAN/A
    Price/FCF-2.05xFCF Yield-48.78%
    Profitability
    Profit Margin0.00%Operating Margin-10009.00%
    ROE-7029.00%ROIC147.21%
    Financial Health
    Debt/Equity-0.43xInterest CoverageN/A
    Current Ratio8.38xQuick Ratio8.38x
    Trading Statistics
    Beta0.76Avg Volume132.96K
    52-Week High$11.0052-Week Low$5.60

    Technical Indicators Dashboard

    As of Nov 16, 2026, the price is 14.1% below its 50-day moving average, and the 50-day average is below the 200-day average. The 14-day RSI is 38.6, in the neutral range between 30 and 70.

    Moving Averages

    SMA 10$6.71
    SMA 20$6.58
    SMA 50$7.08
    SMA 200$7.61
    EMA 10$6.56
    EMA 20$6.65
    EMA 50$7.10
    EMA 200$7.82

    MACD

    Line: -0.15Signal: -0.14Hist: -0.00

    ADX

    ADX: 14.6+DI: 20.9-DI: 22.0

    Aroon & PSAR

    Aroon Up80.0
    Aroon Down20.0
    PSAR$7.83

    Bollinger Bands

    Upper Band$7.26
    Lower Band$5.89
    %B Position2080%(Upper)
    Band Width0.14

    RSI (14-Day)

    Neutral
    38.6

    Momentum Oscillators

    Stoch %K10.0
    Stoch %D23.0
    Williams %R-98.9
    ROC (10d)-4.1%
    Momentum-0.26
    CCI (20d)-102.2
    MFI (14d)27.8

    Volatility Measures

    ATR (14d)$0.49(8.1%)
    StdDev (20d)0.34
    Hist Vol70.5%(High)

    Volume Flow

    VWAP$6.19
    OBV4.8M
    AD Line-2.8M
    CMF (20d)-0.115

    Volume Metrics

    Avg Vol (20d)129.5K
    Vol Ratio0.8x
    VWMA (20d)$6.61

    Pivot Points

    R3$6.69
    R2$6.54
    R1$6.45
    Pivot Point$6.30
    S1$6.21
    S2$6.06
    S3$5.97

    Advanced Oscillators

    TSI-9.82
    Ultimate Osc41.4
    KST-28.54

    Financial Performance

    Related GNG Research

    No research available

    Be the first to write about RNAC

    News

    RNAC Valuation

    Cartesian Therapeutics (RNAC) trades at 25.1x forward earnings.

    Forward P/E
    25.1x
    P/FCF
    -2.0x
    P/B
    -1.4x
    All RNAC metrics

    RNAC Profitability: Margins, ROIC and FCF

    Cartesian Therapeutics (RNAC) has an operating margin of -10009.0% and a net margin of 0.0%. It posts 147.2% ROIC and a -8770.0% FCF margin.

    Operating margin
    -10009.0%
    Net margin
    0.0%
    ROIC
    147.2%
    ROE
    -7029.0%
    FCF margin
    -8770.0%
    FCF yield
    -48.8%
    RNAC financial statements

    Cartesian Therapeutics Competitors

    The companies most similar to Cartesian Therapeutics (RNAC) include SAB Biotherapeutics, Cellectis SA and Sutro Biopharma.

    Sector: Healthcare

    Companies most similar to Cartesian Therapeutics

    RNAC Analyst Ratings

    Cartesian Therapeutics (RNAC) has a Buy consensus from 7 analysts: 7 Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell.

    Consensus
    Buy
    Analysts
    7
    Strong Buy
    1
    Buy
    6
    Hold
    0
    Sell
    0
    Strong Sell
    0
    RNAC stock forecast

    RNAC Bull Case vs Bear Case

    Bull case

    • RNAC earns a 147.2% return on invested capital.
    • 100.0% of RNAC's analyst ratings are Buy or Strong Buy.

    Bear case

    • RNAC's quarterly revenue changed -92.9% year over year.

    RNAC Earnings: Beat Rate and Next Report

    Cartesian Therapeutics (RNAC) beat the EPS estimate in 5 of the last 8 quarters (62.5%). Its next report is expected on Mar 8, 2027.

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    15.8%
    EPS estimate (fiscal period ending Dec 31, 2026)
    -$0.95
    RNAC earnings history

    RNAC Earnings Date

    RNAC reports Mar 8, 2027. The date is estimated.

    Updated Nov 5, 2026. Built from end-of-day prices, company filings and consensus analyst estimates. Methodology

    Frequently Asked Questions About RNAC

    When does RNAC report earnings?

    Cartesian Therapeutics Inc. (RNAC) is expected to report earnings on Mar 8, 2027.

    Does RNAC pay dividends?

    Cartesian Therapeutics Inc. (RNAC) does not currently pay a regular dividend.

    What is RNAC's market cap?

    Cartesian Therapeutics Inc. (RNAC) has a market capitalization of $193.69M with a current stock price of $6.08.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.